Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.65 USD | -1.08% | -12.26% | +19.73% |
May. 03 | Aileron Therapeutics Closes Direct Offering of Shares, Warrants | MT |
May. 01 | Transcript : Aileron Therapeutics, Inc. - Special Call |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 61.95M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -27M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.01
x | P/E ratio 2025 * |
-2.02
x | Employees | 15 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.91% |
Latest transcript on Aileron Therapeutics, Inc.
1 day | -1.08% | ||
1 week | -12.26% | ||
Current month | -19.78% | ||
1 month | -41.13% | ||
3 months | -23.64% | ||
6 months | +146.62% | ||
Current year | +19.73% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
Director of Finance/CFO | 48 | 23-09-30 | |
David Annis
CTO | Chief Tech/Sci/R&D Officer | 51 | 07-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 19-06-18 | |
Alan Musso
BRD | Director/Board Member | 62 | 23-10-30 |
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 3.65 | -1.08% | 44,507 |
24-05-07 | 3.69 | -6.58% | 241,733 |
24-05-06 | 3.95 | +5.05% | 87,757 |
24-05-03 | 3.76 | -1.57% | 142,725 |
24-05-02 | 3.82 | -8.17% | 149,308 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.73% | 61.95M | |
+2.93% | 108B | |
-0.17% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- ALRN Stock